SK14792003A3 - Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok - Google Patents

Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok Download PDF

Info

Publication number
SK14792003A3
SK14792003A3 SK1479-2003A SK14792003A SK14792003A3 SK 14792003 A3 SK14792003 A3 SK 14792003A3 SK 14792003 A SK14792003 A SK 14792003A SK 14792003 A3 SK14792003 A3 SK 14792003A3
Authority
SK
Slovakia
Prior art keywords
amino acids
domain
substances
use according
bacterial
Prior art date
Application number
SK1479-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Frank Mayer
Original Assignee
Novologix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129870A external-priority patent/DE10129870A1/de
Application filed by Novologix Gmbh filed Critical Novologix Gmbh
Publication of SK14792003A3 publication Critical patent/SK14792003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SK1479-2003A 2001-04-30 2002-04-22 Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok SK14792003A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10121145 2001-04-30
DE10129870A DE10129870A1 (de) 2001-04-30 2001-06-21 Antibakterielles Mittel
PCT/EP2002/004410 WO2002087554A2 (de) 2001-04-30 2002-04-22 Ef-tu-bindende substanzen als ntibakterielles mittel

Publications (1)

Publication Number Publication Date
SK14792003A3 true SK14792003A3 (sk) 2004-07-07

Family

ID=26009202

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1479-2003A SK14792003A3 (sk) 2001-04-30 2002-04-22 Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok

Country Status (17)

Country Link
EP (1) EP1397157A2 (de)
JP (1) JP2004534016A (de)
CN (1) CN1298739C (de)
AU (1) AU2002302555B2 (de)
BG (1) BG108399A (de)
BR (1) BR0209282A (de)
CA (1) CA2445995A1 (de)
CZ (1) CZ20033271A3 (de)
EE (1) EE200300530A (de)
HU (1) HUP0401586A3 (de)
IL (1) IL158627A0 (de)
MX (1) MXPA03009954A (de)
NZ (1) NZ529662A (de)
PL (1) PL366836A1 (de)
RU (1) RU2003134636A (de)
SK (1) SK14792003A3 (de)
WO (1) WO2002087554A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229645A1 (de) * 2002-07-02 2004-05-19 Kuchenreuther, Ulrich, Dr. Zellaufschluss von Bakterien
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
JP5852569B2 (ja) 2009-07-31 2016-02-03 タール ファーマシューティカルズ，インコーポレイテッド 結晶化方法および生物学的利用能
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN105218668B (zh) * 2015-10-30 2020-03-24 山东农业大学 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466251A1 (de) * 1990-07-10 1992-01-15 Gist-Brocades N.V. Elfamycin resistente Mutanten
ZA99362B (en) * 1998-01-23 1999-07-19 Akzo Nobel Nv EF-Tu mRNA as a marker for viability of bacteria.
US6451556B1 (en) * 1998-12-21 2002-09-17 Smithkline Beecham Corporation EF-Tu

Also Published As

Publication number Publication date
RU2003134636A (ru) 2005-04-20
HUP0401586A3 (en) 2005-06-28
BG108399A (bg) 2004-08-31
WO2002087554A3 (de) 2003-01-30
EP1397157A2 (de) 2004-03-17
MXPA03009954A (es) 2005-07-25
AU2002302555B2 (en) 2007-08-23
WO2002087554A2 (de) 2002-11-07
JP2004534016A (ja) 2004-11-11
CN1518455A (zh) 2004-08-04
NZ529662A (en) 2006-08-31
CZ20033271A3 (en) 2004-06-16
WO2002087554B1 (de) 2005-01-27
CN1298739C (zh) 2007-02-07
IL158627A0 (en) 2004-05-12
HUP0401586A2 (hu) 2004-11-29
BR0209282A (pt) 2004-07-27
PL366836A1 (en) 2005-02-07
EE200300530A (et) 2004-04-15
CA2445995A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
Hansen et al. Intracellular toxicity of proline-rich antimicrobial peptides shuttled into mammalian cells by the cell-penetrating peptide penetratin
Chen et al. Host defense peptide mimicking peptide polymer exerting fast, broad spectrum, and potent activities toward clinically isolated multidrug-resistant bacteria
Matharu et al. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease
EP1896386B1 (de) Hyaluronsäurebindende peptide fördern die immunabwehr gegen pathogene bakterien
CN109069693B (zh) 多肽及其医疗用途
Xie et al. Novel antimicrobial peptide CPF‐C1 analogs with superior stabilities and activities against multidrug‐resistant bacteria
Rosenfeld et al. Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides
Nakos et al. Septin 2/6/7 complexes tune microtubule plus-end growth and EB1 binding in a concentration-and filament-dependent manner
Lee et al. A cell adhesive peptide from tropoelastin promotes sequential cell attachment and spreading via distinct receptors
SK14792003A3 (sk) Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok
Hansen et al. The anchorless adhesin Eap (extracellular adherence protein) from Staphylococcus aureus selectively recognizes extracellular matrix aggregates but binds promiscuously to monomeric matrix macromolecules
Li et al. Full sequence amino acid scanning of θ-defensin RTD-1 yields a potent anthrax lethal factor protease inhibitor
US8697651B2 (en) Amyloid β fibrillogenesis-inhibiting peptide
US20040198643A1 (en) Antibacterial agent
Thomson et al. Mapping Hsp47 binding site (s) using CNBr peptides derived from type I and type II collagen
US7659366B2 (en) Peptide with putative role in cytoskeletal protection
Jia et al. Tryptic Stability and Antimicrobial Activity of the Derivatives of Polybia-CP with Fine-Tuning Modification in the Side Chain of Lysine
KR100628917B1 (ko) 세포장해 단백질 및 그 이용
JPH07500342A (ja) 生物学的活性ペプチドおよび抗生物質を有する組成物およびこれを用いた治療
Zobiak Fibronectin binding protein A-mediated cellular infections by Staphylococcus aureus (Rosenbach, 1884)
Zobiak Fibronectin binding protein A-mediated cellular infections by Staphylococcus aureus
US20060241031A1 (en) Assay
JPS61243025A (ja) 殺菌性ペプチド